FY2028 EPS Estimates for Alnylam Pharmaceuticals, Inc. Boosted by Analyst (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at HC Wainwright boosted their FY2028 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings per share of $24.00 for the year, up from their previous forecast of $23.82. HC Wainwright currently has a "Buy" rating and a $395.00 price objective on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($4.61) per share.

A number of other analysts have also weighed in on the stock. The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Monday. BMO Capital Markets reiterated an "outperform" rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Chardan Capital decreased their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating on the stock in a report on Friday, February 16th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, April 5th. Nine analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $216.12.

Alnylam Pharmaceuticals Stock Down 0.2 %

ALNY stock traded down $0.32 during mid-day trading on Thursday, hitting $152.09. The company had a trading volume of 473,409 shares, compared to its average volume of 822,936. The company has a market capitalization of $19.16 billion, a price-to-earnings ratio of -42.42 and a beta of 0.39. Alnylam Pharmaceuticals has a 12-month low of $143.52 and a 12-month high of $218.88. The company has a 50-day moving average price of $154.94 and a 200 day moving average price of $168.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. During the same period in the prior year, the business posted ($1.68) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 31.2% on a year-over-year basis.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company's stock worth $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Eventide Asset Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $16,653,000. Public Employees Retirement System of Ohio grew its stake in shares of Alnylam Pharmaceuticals by 1.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 55,417 shares of the biopharmaceutical company's stock worth $10,607,000 after buying an additional 747 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $720,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.